Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment.

Details

Language :

English

ISSN :

00257974

Volume :

97

Issue :

23

Database :

Complementary Index

Journal :

Medicine

Publication Type :

Academic Journal

Accession number :

130418799

Full Text :

https://doi.org/10.1097/MD.0000000000011081